AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2024
Jun 5, 2024
31542_dirs_2024-06-05_261acfd0-c33c-4a1b-8195-ebee6f7e1f2e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2024-06-04
Reporting Person: Daly Richard J (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-04 | Common stock, par value $0.001 per share | M | 40000 | $4.01 | Acquired | 252147 | Direct |
| 2024-06-04 | Common stock, par value $0.001 per share | S | 17323 | $15.975 | Disposed | 234824 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-04 | Options to purchase common stock | $4.01 | M | 40000 | Disposed | 2025-01-02 | Common Stock (40000) | Direct |
Footnotes
F1: Shares were sold on the open market in order to fund the exercise price and tax withholding of the exercise of the stock option.
F2: Derivative securities vested in three annual tranches beginning on January 2, 2019.
More from CATALYST PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 11
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Regulatory Filings
2026
Jan 12
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6
Director's Dealing
2025
Dec 30